Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nello Buccianti"'
Autor:
Antonino Carlo Privitera, Antonio Rispo, C. Ferracane, Maria Cappello, Raffaele Melina, Francesco William Guglielmi, Angelo Andriulli, Rocco Spagnuolo, Fabrizio Bossa, Giuseppe Costantino, M. Mendolaro, Mariabeatrice Principi, Agnese Miranda, Pietro Paese, Alessandro Azzarone, Ladislava Sebkova, Silvia Mazzuoli, Olga Maria Nardone, R. Clemente, Antonio Tursi, Marco Romano, M. Patturelli, A. Lauria, Endrit Shahini, C. Ricciardelli, Caterina Sgarro, L. Fanigliulo, Laurino Grossi, Gabriele Riegler, Walter Fries, Giuseppe Pranzo, Nello Buccianti, Gaetano Inserra, Giuseppe Biscaglia, Maria Rosa Valvano
Publikováno v:
Digestive diseases and sciences. 65(6)
Golimumab is a new anti-TNF-alpha monoclonal antibody for patients with ulcerative colitis. To assess the short- and long-term effectiveness and safety of golimumab in daily clinical practice and to identify predictors of response. Consecutive patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9e55e1b6e0c2abaf9b5ee1bc38def14
https://pubmed.ncbi.nlm.nih.gov/31722059
https://pubmed.ncbi.nlm.nih.gov/31722059
Autor:
Nicola Della Valle, Giacomo Forti, Roberto Lorenzetti, Nello Buccianti, Giuseppe Pranzo, Marcello Picchio, C. Ricciardelli, Costantino Zampaletta, Francesco Luzza, A. Lauria, Leonardo Allegretta, Walter Elisei, Antonio Tursi, Tiziana Larussa, Natale Polimeni, Antonio Penna, Roberto Faggiani, Sara Gallina, Yusef Hadad, G. Mocci
Publikováno v:
Journal of gastrointestinal and liver diseases : JGLD. 26(3)
Background & Aims: Golimumab (GOL) has been recently approved in Italy for the treatment of ulcerative colitis (UC) unresponsive to standard treatments. Our aims were to assess the real-life efficacy and safety of GOL in managing UC outpatients in It
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcbfc80a64d8f03b3b3ee19d8dff3a87
https://pubmed.ncbi.nlm.nih.gov/28922435
https://pubmed.ncbi.nlm.nih.gov/28922435
Autor:
Giuseppe Corritore, Vania C. Liuzzi, Vito Annese, Orazio Palmieri, Tiziana Latiano, Massimo Carella, Nello Buccianti, Teresa Maria Creanza, Giuseppina Martino, Giuseppe Biscaglia, R. Anglani, Daniela Scimeca, Anna Latiano, Angelo Andriulli
Publikováno v:
Gastroenterology. 144:S-470
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1db939ed99b71dfb6f4b59b9541ac7e4
https://doi.org/10.1016/s0016-5085(13)61741-2
https://doi.org/10.1016/s0016-5085(13)61741-2
Autor:
Piero Luigi Almasio, Fabrizio Bossa, A. Lauria, Maria Cappello, Giuseppe Costantino, Nello Buccianti, Antonino Carlo Privitera, Fabiana Castiglione, R. Marasco, Mauro Mastronardi, Walter Fries, Marta Mazza, Antonio Rispo
Publikováno v:
Gastroenterology. 144:S-436
Background and aim: Infliximab (IFX) has been shown effective both for induction and maintenance of remission in moderate-to-severely active ulcerative colitis (UC). The aim of this retrospective multicenter study is to provide data on short and long
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5116546de17d5f0ceb64fb0a7ec387a
https://doi.org/10.1016/s0016-5085(13)61604-2
https://doi.org/10.1016/s0016-5085(13)61604-2
Autor:
Angelo Andriulli, Giuseppe Biscaglia, Maria Rosa Valvano, Nello Buccianti, Orazio Palmieri, Daniela Scimeca, Anna Latiano, Renata D'Incà, Vito Annese
Publikováno v:
Gastroenterology. 144:S-471
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::825845f71f50bed44b88e4c15b71c6c6
https://doi.org/10.1016/s0016-5085(13)61745-x
https://doi.org/10.1016/s0016-5085(13)61745-x